TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27010143

Group type: EXPERIMENTAL
Intervention: Lamivudine (LMV)
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Telbivudine (LdT)
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Adefovir Dipivoxil (ADV)
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: LMV + ADV
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Control group (LMV, ADV, LdT)
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: LMV + ADV and ETV
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: ETV
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: LMV
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1332
Study: 25277061

Group type: EXPERIMENTAL
Intervention: Flurbiprofen lozenges (new generic formulation by Epifarma Srl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benactiv Gola® (originator reference product)
Number of subjects: 0
Study: 22708825

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 1105
Study: 20023215

Group type: EXPERIMENTAL
Intervention: Concurrent rituximab (375 mg/m2) plus infusional EPOCH chemotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sequential rituximab (375 mg/m2) after completion of all chemotherapy
Number of subjects: 101
Study: 17403790

Group type: EXPERIMENTAL
Intervention: Lateral entry pin fixation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Medial and lateral entry pin fixation
Number of subjects: 52
Study: 16372229

Group type: EXPERIMENTAL
Intervention: hGH treatment for 24 months
Number of subjects: 19
Study: 11943523

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 30
Study: 9583550

Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fentanyl-isoflurane anesthesia
Number of subjects: 70
Study: 8092112

Group type: EXPERIMENTAL
Intervention: Cisplatin and lipiodol chemoembolization
Number of subjects: 20
Study: 2684383

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DX) 75 mg/m2 IV every 3 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Idarubicin (IDA) 45 mg/m2 orally every 3 weeks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DX)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Idarubicin (IDA)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 76
Study: 30385250

Group type: EXPERIMENTAL
Intervention: Healthy Eating and Active Living Taught at Home (HEALTH) intervention
Number of subjects: 179

Group type: COMPARATOR
Intervention: PAT usual care
Number of subjects: 179
Study: 27645465

Group type: EXPERIMENTAL
Intervention: Chiropractic manipulative therapy (CMT) - four treatments over 2 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control group - no treatment
Number of subjects: 120
Study: 24239802

Group type: EXPERIMENTAL
Intervention: Early surgery strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged conservative care with surgery if needed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in extent of VESC after 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: No VESC at 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 1 VESC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 2 VESC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both types 1 and 2 VESC
Number of subjects: 0
Study: 22302849

Group type: EXPERIMENTAL
Intervention: Fixed-dose artesunate-amodiaquine regimen
Number of subjects: 0
Study: 20881281

Group type: EXPERIMENTAL
Intervention: Prolonged perineural infusion of 0.5% ropivacaine at 5 mL/h for 4 to 83 days post-surgery
Number of subjects: 71
Study: 18565156

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 microg/kg)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Ondansetron (1, 4, or 16 microg/kg twice daily)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 17217744

Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12824793

Group type: EXPERIMENTAL
Intervention: Tailored minimal self-help intervention (mailed self-help magazine, condom samples, condom-carrying case, booster newsletter)
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: Tailored minimal self-help intervention
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1210
Study: 10629434

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (D-FEN) 15 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ipsapirone (IPS) 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined challenge tests (D-FEN and IPS)
Number of subjects: 16
Study: 8997012

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antacid suspension
Number of subjects: 0
Study: 7956716

Group type: EXPERIMENTAL
Intervention: Dimethyl APD (3‐dimethylamino‐1‐hydroxypropylidene‐1, 1‐bisphosphonate) at doses of 50, 100, 200, and 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamidronate (3‐amino‐1‐hydroxypropylidene‐1, 1‐bisphosphonate) at doses of 300, 600, and 900 mg
Number of subjects: 0
Study: 2434791

Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 12
Study: 31286913

Group type: EXPERIMENTAL
Intervention: Toric intraocular lens with capsular tension ring (CTR)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Toric intraocular lens without capsular tension ring (CTR)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (overall sample)
Number of subjects: 179
Study: 27333127

Group type: EXPERIMENTAL
Intervention: Individualized symptom management strategies for CRF
Number of subjects: 47
Study: 28240566

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive randomization treatment regimens
Number of subjects: 750

Group type: COMPARATOR
Intervention: Bayesian adaptive randomization
Number of subjects: 750
Study: 23826760

Group type: EXPERIMENTAL
Intervention: High dose of oral sodium bicarbonate with a serum target HCO3- level of 24±1 mmol/L
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rescue therapy of sodium bicarbonate with a serum target level of 20±1 mmol/L
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High dose of oral sodium bicarbonate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rescue therapy of sodium bicarbonate
Number of subjects: 200
Study: 21839405

Group type: EXPERIMENTAL
Intervention: Lenalidomide and high-dose dexamethasone (Len+Dex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone alone (Dex)
Number of subjects: 0
Study: 19259967

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16877721

Group type: EXPERIMENTAL
Intervention: rhEndostatin administered as a bid subcutaneous injection at a starting dose of 60 mg/m2/d, escalated to 90 mg/m2/d if necessary
Number of subjects: 42
Study: 15265253

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 11386930

Group type: EXPERIMENTAL
Intervention: Intravenous alpha‐gal A (0.2 mg/kg every other week for 12 doses)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8928459

Group type: EXPERIMENTAL
Intervention: Self-examination group
Number of subjects: 122471

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122471

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 122471

Group type: EXPERIMENTAL
Intervention: Patients aged 50-59
Number of subjects: 122471
Study: 1985618

Group type: EXPERIMENTAL
Intervention: Intra-articular methylprednisolone and lidocaine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intrabursal methylprednisolone and lidocaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intra-articular lidocaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intrabursal lidocaine
Number of subjects: 48
Study: 6403000

Group type: EXPERIMENTAL
Intervention: Oral neomycin and erythromycin base plus parenteral placebo
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: Oral neomycin and erythromycin base plus parenteral cephalothin sodium
Number of subjects: 1128
Study: 30738199

Group type: EXPERIMENTAL
Intervention: End-of-life care simulation with standardized patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no simulation)
Number of subjects: 38
Study: 28283937

Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment initiated at 2 weeks after hemiarthroplasty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bisphosphonate treatment initiated at 12 weeks after hemiarthroplasty
Number of subjects: 100
Study: 26374766

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: BQ-123 (ETA receptor blocker)
Number of subjects: 119
Study: 23968656

Group type: EXPERIMENTAL
Intervention: 30 mL of 0.375% ropivacaine combined with 1 μg kg(‐1) of dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 30 mL of 0.375% ropivacaine combined with saline (control)
Number of subjects: 40
Study: 21270672

Group type: EXPERIMENTAL
Intervention: Boston EO lenses (Dk/t: 26)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Boston XO lenses (Dk/t: 46)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both lens materials
Number of subjects: 11
Study: 19470152

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (H)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monopolar Diathermy (M)
Number of subjects: 0
Study: 17370498

Group type: EXPERIMENTAL
Intervention: Uylabris
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Seeds of Brassica Alb (0.05 g each point)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Seeds of Brassica Alb (0.01 g each point)
Number of subjects: 175
Study: 15342211

Group type: EXPERIMENTAL
Intervention: TAFI antigen levels in patients with preeclampsia
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAFI antigen levels in normal pregnant women (control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of TAFI antigen levels between preeclamptic patients and normal pregnant women
Number of subjects: 60
Study: 11133625

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control Group (sterile water)
Number of subjects: 50
Study: 9772137

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet with 15% of energy as protein
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard-protein (SP) diet with 7.5% energy as protein
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard-protein (SP) diet
Number of subjects: 69
Study: 7598068

Group type: EXPERIMENTAL
Intervention: Daily dietary supplementation with > or = 10 g n-3 fatty acids from fish oil for > 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsupplemented control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined values for all subjects
Number of subjects: 0
Study: 2911877

Group type: EXPERIMENTAL
Intervention: Supine position with 1 mg bumethanide intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Upright position with 1 mg bumethanide intravenously
Number of subjects: 12
Study: 1099898

Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 31417013

Group type: EXPERIMENTAL
Intervention: Targeted antibiotics (TA) based on rectal swab culture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Empirical antibiotics (EA) - standard parenteral ciprofloxacin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison between TA and EA
Number of subjects: 100
Study: 28099054

Group type: EXPERIMENTAL
Intervention: Full Code
Number of subjects: 533

Group type: COMPARATOR
Intervention: DNR/DNI
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Noninvasive interventions (e.g., blood cultures, medications, imaging)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Aggressive or invasive options (e.g., dialysis, bronchoscopy, surgical consultation, transfer to ICU)
Number of subjects: 533
Study: 25853370

Group type: EXPERIMENTAL
Intervention: Methamphetamine (10 mg or 20 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (in both studies)
Number of subjects: 19
Study: 23873217

Group type: EXPERIMENTAL
Intervention: PEG-IFN/RBV
Number of subjects: 474
Study: 21723766

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2901

Group type: EXPERIMENTAL
Intervention: Mailed notification to primary care physicians (alert letter, BMD requisition, and management flowchart)
Number of subjects: 2901

Group type: EXPERIMENTAL
Intervention: Both physician notifications and patient notification (alert letter)
Number of subjects: 2901
Study: 19689979

Group type: EXPERIMENTAL
Intervention: Cognitive aid (poster detailing the NRP algorithm)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no cognitive aid)
Number of subjects: 32
Study: 17116264

Group type: EXPERIMENTAL
Intervention: Computerized classification system for visual field defects
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Visual fields without adjustment factor
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Visual fields with adjustment factor
Number of subjects: 189
Study: 15181049

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg daily for 6 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 22
Study: 10785452

Group type: EXPERIMENTAL
Intervention: Subjects with HD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 24
Study: 9483215

Group type: EXPERIMENTAL
Intervention: Glucocorticoids, mineralocorticoids, and catecholamines
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sex hormones
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Scirrhous carcinomas
Number of subjects: 110
Study: 8141717

Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (t‐PA)
Number of subjects: 5711

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5711
Study: 3520315

Group type: EXPERIMENTAL
Intervention: Hydralazine (300 mg per day) and Isosorbide dinitrate (160 mg per day)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Prazosin (20 mg per day)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 29861260

Group type: EXPERIMENTAL
Intervention: Intensified active treatment with additional mobilization and strength training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 39
Study: 27546744

Group type: EXPERIMENTAL
Intervention: AT+rhTM
Number of subjects: 129

Group type: COMPARATOR
Intervention: AT
Number of subjects: 129
Study: 24758169

Group type: EXPERIMENTAL
Intervention: Home group (3‐month SMS reminder and home‐collection)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Clinic group (3‐month SMS reminder to return to the clinic)
Number of subjects: 600
Study: 23230745

Group type: EXPERIMENTAL
Intervention: Single injection of low dose (0.5 g) cefozopran hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single injection of middle dose (1.0 g) cefozopran hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single injection of high dose (2.0 g) cefozopran hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple doses (1.0 g) injection of cefozopran hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Urinary excretion of cefozopran within 24 h
Number of subjects: 24
Study: 21035610

Group type: EXPERIMENTAL
Intervention: 8-session group cognitive behavior therapy (CBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Time-matched comparison group condition
Number of subjects: 100
Study: 18806051

Group type: EXPERIMENTAL
Intervention: Low-dose propofol (3 mg.kg(‐1).h(‐1))
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 microg.kg(‐1).h(‐1))
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Isoflurane (end‐tidal concentration of 0.2%)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 150

Group type: COMPARATOR
Intervention: Pre-extubation phase
Number of subjects: 150
Study: 16104440

Group type: EXPERIMENTAL
Intervention: Local infiltration with bupivacaine and pre-incisional intramuscular (IM) ketorolac (group BK)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Saline local infiltration IM (group NN)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Local infiltration with bupivacaine and saline IM (group BN)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Local infiltration with saline and ketorolac IM (group NK)
Number of subjects: 83
Study: 11796545

Group type: EXPERIMENTAL
Intervention: GR79236 (10 microgram/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GR79236
Number of subjects: 25
Study: 10048106

Group type: EXPERIMENTAL
Intervention: Health and nutrition education program
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 288
Study: 7566405

Group type: EXPERIMENTAL
Intervention: Gammaglobulin (10 g doses at 3-day intervals)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (10 g of albumin)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gammaglobulin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Gammaglobulin and Placebo
Number of subjects: 71
Study: 1971592

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICI 118 551 (control)
Number of subjects: 0
Study: 7235737

Group type: EXPERIMENTAL
Intervention: Oral retinoid Ro 10‐9359 (75 mg/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31129805

Group type: EXPERIMENTAL
Intervention: Prosopis juliflora pods at 10%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Prosopis juliflora pods at 20%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Prosopis juliflora pods at 30%
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control diet (no Prosopis juliflora pods)
Number of subjects: 64
Study: 27653153

Group type: EXPERIMENTAL
Intervention: Nordic Walking training (12-week, 60-minute sessions, 3 times per week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 25597699

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (240 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Panax ginseng (1200 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24008683

Group type: EXPERIMENTAL
Intervention: Text messaging (SMS)‐based smoking cessation program
Number of subjects: 0
Study: 21832958

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) monotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: CNI standard therapy
Number of subjects: 150
Study: 19398378

Group type: EXPERIMENTAL
Intervention: Glove electrode TENS (continuous stimulus, 100 Hz, strong but comfortable intensity for 30 minutes)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Standard electrode TENS (100 Hz for 30 minutes)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo TENS using a glove electrode (burst stimulus, 100 Hz, 5-second cycle time for 42 seconds, then 0 mA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 56
Study: 17907113

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30-45 mg/day)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Gliclazide (80-320 mg/day)
Number of subjects: 283
Study: 15377582

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11729367

Group type: EXPERIMENTAL
Intervention: Bedside coagulometer (Hemochron) measuring b-APTT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Duplicate measurements of b-APTT on the Hemochron coagulometer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: APTT ratio of 1.5-2.5
Number of subjects: 20
Study: 9530343

Group type: EXPERIMENTAL
Intervention: Aphidicolin (APC) treatment in PHA-stimulated lymphocyte cultures
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (no APC treatment)
Number of subjects: 65
Study: 8055852

Group type: EXPERIMENTAL
Intervention: Maternal vegetarian diet
Number of subjects: 146

Group type: COMPARATOR
Intervention: Maternal omnivore diet
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study: 2587826

Group type: EXPERIMENTAL
Intervention: Concurrent instruction (two sessions per day, random presentation of two words)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Isolation-intermix instruction (two sessions per day, separate daily sessions for each word followed by random presentation)
Number of subjects: 4
Study: 4571196

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (long-acting phenothiazine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29229343

Group type: EXPERIMENTAL
Intervention: High-speed drill with automatic irrigation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-speed drill with manual irrigation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ultrasonic bone-cutting knife with automatic irrigation (USBCD)
Number of subjects: 90
Study: 28166188

Group type: EXPERIMENTAL
Intervention: Focused and Corrective Feedback (FCF)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Structured and Supported Debriefing (SSD)
Number of subjects: 95